- Home
- ESGL vs PBYI Comparison
ESGL vs PBYI Comparison
Compare ESGL & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESGL
- PBYI
- Stock Information
- Founded
- ESGL 1999
- PBYI 2010
- Country
- ESGL Singapore
- PBYI United States
- Employees
- ESGL N/A
- PBYI N/A
- Industry
- ESGL
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- ESGL
- PBYI Health Care
- Exchange
- ESGL Nasdaq
- PBYI Nasdaq
- Market Cap
- ESGL 154.3M
- PBYI 171.7M
- IPO Year
- ESGL N/A
- PBYI N/A
- Fundamental
- Price
- ESGL $3.69
- PBYI $4.47
- Analyst Decision
- ESGL
- PBYI Strong Buy
- Analyst Count
- ESGL 0
- PBYI 1
- Target Price
- ESGL N/A
- PBYI $7.00
- AVG Volume (30 Days)
- ESGL 22.8K
- PBYI 679.9K
- Earning Date
- ESGL 09-23-2025
- PBYI 11-06-2025
- Dividend Yield
- ESGL N/A
- PBYI N/A
- EPS Growth
- ESGL N/A
- PBYI 434.29
- EPS
- ESGL N/A
- PBYI 0.97
- Revenue
- ESGL $6,099,784.00
- PBYI $238,062,000.00
- Revenue This Year
- ESGL N/A
- PBYI N/A
- Revenue Next Year
- ESGL N/A
- PBYI N/A
- P/E Ratio
- ESGL N/A
- PBYI $4.60
- Revenue Growth
- ESGL N/A
- PBYI 8.63
- 52 Week Low
- ESGL $0.90
- PBYI $2.32
- 52 Week High
- ESGL $3.87
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- ESGL 73.44
- PBYI 45.38
- Support Level
- ESGL $3.33
- PBYI $4.49
- Resistance Level
- ESGL $2.70
- PBYI $5.22
- Average True Range (ATR)
- ESGL 0.24
- PBYI 0.28
- MACD
- ESGL 0.10
- PBYI -0.13
- Stochastic Oscillator
- ESGL 91.63
- PBYI 5.83
About ESGL ESGL Holdings Limited
ESGL Holdings Ltd is a waste management, treatment, and recycling company involved in the collection and recycling of hazardous and non-hazardous industrial waste from customers such as pharmaceutical, semiconductor, petrochemical, and electroplating companies.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.